Patents Assigned to IMMUTEP
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20230149541
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: January 18, 2023
    Publication date: May 18, 2023
    Applicant: IMMUTEP
    Inventor: Frederic TRIEBEL
  • Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
    Patent number: 11583582
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: February 21, 2023
    Assignee: IMMUTEP
    Inventor: Frederic Triebel
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20190175726
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: February 13, 2019
    Publication date: June 13, 2019
    Applicant: IMMUTEP
    Inventor: Frederic TRIEBEL
  • Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
    Patent number: 10232038
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: March 19, 2019
    Assignee: IMMUTEP
    Inventor: Frederic Triebel
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20170119876
    Abstract: The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Applicant: IMMUTEP
    Inventor: Frederic TRIEBEL
  • Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
    Patent number: 9579382
    Abstract: The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 28, 2017
    Assignee: IMMUTEP
    Inventor: Frédéric Triebel
  • USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE
    Publication number: 20110008331
    Abstract: The present disclosure relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 13, 2011
    Applicant: IMMUTEP
    Inventor: Frédéric Triebel